Medical marijuana company Creso Pharma (ASX:CPH) has just entered the emerging $100 billion global market for psychedelic medicine with acquisition of Canada-based Halucenex Life Sciences.

The agreement provides Creso Pharma with entry into the emerging global market for psychedelics medicines – estimated to be worth up to US$100Bn.

The acquisition marks the first fully-owned psychedelic medicines company on the ASX.

Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company. As a result of the acquisition, it will benefit from significant synergies including Creso Pharma’s experienced pharmaceutical product development team, industry leading advisers, a comprehensive global distribution network and a top-tier premium cannabis cultivation facility.

Watch the interview below with Creso strategic advisor, Bruce Linton, and  founder of Canopy Growth (NYSE:CGC), the world’s largest cannabis company share his thoughts on the acquisition.

This article was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreCannabis

Featured Companies

You might be interested in